Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 812 results for "bristol myers squibb"

FDA Approves New Indication for Opdivo
Monthly Prescribing Reference

FDA Approves Opdivo, First Immunotherapy for Lung Cancer

Nivolumab ( Opdivo , Bristol-Myers Squibb Company) is the first immunotherapy to be available for use in the treatment of lung cancer. The drug has just been approved by the US Food and Drug Administration (FDA) for use in patients with ... General Medicine eJournal, 3 hours ago
Bristol-Myers Lung Cancer Drug Opdivo Wins Speedy OK Investor's Business Daily, 4 hours ago

70 images for bristol myers squibb

Irish Times, 1 week ago
Augusta Chronicle, 1 week ago
OncLive, 5 days ago
Jutia Group, 1 week ago
KPCB, 1 week ago
Pharma Letter, 2 weeks ago
Jutia Group, 3 weeks ago
HR Grapevine, 1 week ago
Pharmafocus, 1 week ago, 1 month ago

Bristol-Myers Squibb: This Is the Fastest Approval Ive Seen

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes. Markets are closed on certain holidays. Stock Market Holiday List By accessing this page, ...
 BioSpace4 hours ago Bristol-Myers Squibb Hits All-Time High Off FDA Approval For Expanded Use Of Opvido  Benzinga.com5 hours ago Bristol-Myers Squibb Canada Announces Hepatitis C Cure Rate of 97% in Study of Patients Co-infected with HIV Given 12-week Combination Treatment of Daclatasvir and Sofosbuvir in ALLY-2 Trial  Benzinga.com1 day ago Lilly to test combinations with Merck, Bristol-Myers' cancer drugs  Reuters1 month ago

Bristol-Myers Wins Early Approval to Use Opdivo for Lung Cancer

(Bloomberg) -- Bristol-Myers Squibb Co. won expanded U.S. approval for its drug Opdivo to treat lung cancer, more than three months ahead of schedule and just weeks after final clinical-trial results became available. The Food and Drug ...
 Bloomberg4 hours ago Bristol-Myers' Cancer Immunotherapy Opdivo Wins Approval to Treat Lung Cancer  TheStreet.com5 hours ago Bristol-Myers bags a record-fast approval for its cancer blockbuster Opdivo  FierceBiotech5 hours ago Bristol-Myers takes a big step in its PD-1 lung cancer race with Merck  FierceBiotech2 days ago
Copenhagen Post

Bavarian Nordic shares soar as massive cancer deal is signed

Bristol-Myers Squibb have option to license and commercialise BN's prostate cancer vaccine Prostvac (Photo: Bavarian Nordic) 14:59 The Danish biotech company Bavarian Nordic has been on the rise since it announced that it was part of a ...
 Copenhagen Post8 hours ago Bristol-Myers To License Bavarian Nordic's Prostvac For Up To $975 Mln  RTTNews.com18 hours ago Bavarian Nordic Could Tally up to $975M in Prostate Cancer Deal with BMS  Genetic Engineering News5 hours ago BMS, Bavarian Nordic In Exclusive PROSTVAC Pact  Contract Pharma6 hours ago

Bristol Myers Squibb : Reports Summarize Melanomas Findings from Bristol-Myers Squibb (Nivolumab in Previously Untreated Melanoma without BRAF Mutation)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators publish new report on Oncology. According to news reporting originating in Wallingford, Connecticut , by NewsRx journalists, research stated, "Nivolumab was associated ...
 4 Traders8 hours ago ALLY-2 trial demonstrates 97% SVR12 rates in patients with hepatitis C co-infected with HIV after 12-week regimen of daclatasvir and sofosbuvir  Medical News Today11 hours ago Bristol-Myers: ALLY-2 Phase 3 Trial Achieves Hepatitis C Cure Rate Of 97%  RTTNews.com1 day ago Bristol Myers Squibb : ALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After Ribavirin-Free Investigational 12-Week Regimen of...  4 Traders6 hours ago

Bristol-Myers Files for New Indications for Yervoy, Opdivo - Analyst Blog

Bristol-Myers Squibb Company BMY announced that the FDA has accepted its supplemental biologics license application (BLA) for Yervoy as an adjuvant treatment of patients suffering from stage-III melanoma, who are at high risk of recurrence ...
 Zacks.com1 day ago

Bristol-Myers Squibb's $1.6 Billion On New Drug Deals Is Well Spent

Bristol-Myers Squibb (NYSE:BMY) recently entered a couple of agreements worth $1.6 billion to bolster its immuno-oncology drugs portfolio. The first was its decision to acquire Flexus Biosciences, which is involved in the development of novel ...
 Trefis1 day ago

A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design

† Department of Computer-Assisted Drug Design, Bristol-Myers Squibb Research and Development, 5 Research Parkway Wallingford Connecticut 06492, United States‡ Department of Discovery Chemistry, Bristol-Myers Squibb Research and Development, 5 ...
 Journal of Medicinal Chemistry1 day ago Blood-Brain Barrier Technologies Market - Global Industry Analysis and Forecast 2014 - 2020  Digital Journal5 hours ago Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc.  Virtual Strategy Magazine11 hours ago Global Systemic Sclerosis (Scleroderma) Therapeutics Pipeline Review 2015 - 22 Companies & 31 Drug Profiles  Individual.com12 hours ago

BRISTOL MYERS SQUIBB : Hepatitis C cure rate of 97 per cent announced in study of patients co-infected with HIV given 12-week combination treatment of daclatasvir and sofosbuvir in ALLY-2 trial

Patient population with both infections historically challenging to treat due to drug-drug interactions. MONTREAL , March 3, 2015 /CNW/ -A combination of two once-daily medications for chronic hepatitis C infection has been shown in newly released ...
 4 Traders1 day ago High rate of lymphoma patients respond to Bristol-Myers drug: study  Reuters2 months ago Hepatitis C cure rate of 97 per cent announced in study of patients co-infected with HIV given 12-week combination treatment of daclatasvir and sofosbuvir in ALLY-2 trial  Pharmacy Choice1 day ago

Melanoma Treatment Under Review for Preventing, Delaying Recurrence

Share this article: Bristol-Myers Squibb announced that the FDA has accepted for filing and review the supplemental Biologics License Application (sBLA) for Yervoy (ipilimumab) for the adjuvant treatment of patients with stage 3 ...
 Renal & Urology News1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - bristol myers squibb
Get updated on latest news & your favorite topics right in your inbox!
More     Less